Agios Corp (AGIO) - מקדם חוב לטווח ארוך להון

Agios Pharmaceuticals (AGIO) relies on cutting-edge developments in enzyme bioengineering to combat rare blood pathologies. The firm's environmental policy is based on minimizing water resource usage and the safe synthesis of drugs. Patent protection and the monetization of previous developments guarantee business sustainability, with the indicator standing at 0.01. This price action chart confirms these fundamental advantages and the company's high scientific potential.

Stable royalties from oncology patents provide Agios Pharmaceuticals (AGIO) with a solid financial foundation, minimizing reliance on external borrowing. The long-term debt-to-equity ratio quantifies this balance, allowing investors to assess undercapitalization risk against the issuer's reliability, which is clearly reflected in the long-term debt-to-equity price action.